ELMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

18.05M

+11.04%

0.260

+18.18%

17.82M

+13.6%

0.242

+15.48%

19.24M

+10.63%

0.297

+19%

Estimates Revision

The market is revising Upward the revenue expectations for Electromed, Inc. (ELMD) for FY2026, with the revenue forecasts being adjusted by 0.07% over the past three months. During the same period, the stock price has changed by 23.62%.

Revenue Estimates for FY2026

Revise Upward

+0.07%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+5.04%

In Past 3 Month

Stock Price

Go Up

+23.62%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ELMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELMD is 36.67 USD with a low forecast of 36.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 29.880

Low

36.00

Averages

36.67

High

38.00

Current: 29.880

Low

36.00

Averages

36.67

High

38.00

Roth Capital

Buy

maintain

$35 -> $36

2025-11-13

Reason

Roth Capital

Price Target

$35 -> $36

2025-11-13

maintain

Buy

Reason

Roth Capital raised the firm's price target on Electromed to $36 from $35 and keeps a Buy rating on the shares. The company's Q1 results were above expectations and the management reiterated its goal to drive double-digit top-line growth and expanded operating leverage, the analyst tells investors in a research note. The company's best-in-class high frequency chest wall oscillation device continues to take share in a highly underdiagnosed bronchiectasis market, the firm added.

Roth Capital

Kyle Bauser

Buy

maintain

$29 -> $35

2025-08-27

Reason

Roth Capital

Kyle Bauser

Price Target

$29 -> $35

2025-08-27

maintain

Buy

Reason

Roth Capital analyst Kyle Bauser raised the firm's price target on Electromed to $35 from $29 and keeps a Buy rating on the shares. The company reported better-than-expected results and outlined the expectation in FY26 to deliver double-digit top-line growth with expanded operating leverage, the analyst tells investors in a research note. Electromed shares remain highly undervalued given the company's market-leading position within the underserved bronchiectasis space, strong earning's profile, clean balance sheet, and improving operating efficiencies, Roth added.

Lake Street

Ben Haynor

initiated

$36

2025-08-27

Reason

Lake Street

Ben Haynor

Price Target

$36

2025-08-27

initiated

Reason

Lake Street analyst Ben Haynor assumed coverage of Electromed with a Buy rating and $36 price target. Electromed reported "solid" Q4 results and the firm does not believe "heroic efforts are required" by Electromed to drive continued strong performance, the analyst tells investors. The firm expects Electromed to be able to post consistent double-digit revenue growth in the years to come with operating leverage to follow, the analyst added.

Roth Capital

initiated

$29

2025-07-21

Reason

Roth Capital

Price Target

$29

2025-07-21

initiated

Reason

Roth Capital initiated coverage of Electromed with a Buy rating and $29 price target. The company, which is focused on developing, manufacturing, and marketing noninvasive airway clearance therapy devices, is taking share by "offering a better technology with a pure-play focus and expanding the market with new clinical evidence and physician education," the analyst tells investors. The firm believes the company can continue to post double-digit revenue growth with "meaningful operating leverage," the analyst added.

B. Riley Securities

Kyle Bauser

Strong Buy

Initiates

$38

2025-02-20

Reason

B. Riley Securities

Kyle Bauser

Price Target

$38

2025-02-20

Initiates

Strong Buy

Reason

B. Riley analyst Kyle Bauser initiated coverage of Electromed with a Buy rating and $38 price target. Electromed is a profitable, growing medical device company that manufactures and sells high-frequency chest wall oscillation airway clearance products for patients with chronic respiratory conditions, the analyst tells investors in a research note. The firm believes the company can reach $1.00 per share of earnings by fiscal 2026 and reach 20% operating margins over time. Electromed is also an attractive takeout target for a larger medical technology strategy looking to leverage the pulmonologist call point, contends B. Riley.

Valuation Metrics

The current forward P/E ratio for Electromed Inc (ELMD.A) is 27.33, compared to its 5-year average forward P/E of 29.84. For a more detailed relative valuation and DCF analysis to assess Electromed Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

29.84

Current PE

27.33

Overvalued PE

38.28

Undervalued PE

21.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

16.18

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

21.78

Undervalued EV/EBITDA

10.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.36

Current PS

0.00

Overvalued PS

2.98

Undervalued PS

1.75

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ELMD News & Events

Events Timeline

No data

News

4.0

11-14NASDAQ.COM

Electromed (ELMD) Receives Upgrade to Buy: Reasons Explained

9.5

11-13NASDAQ.COM

Electromed, Inc. (ELMD) Exceeds Q1 Earnings and Revenue Projections

9.5

11-11NASDAQ.COM

Stereotaxis Inc. (STXS) Announces Q3 Loss and Falls Short of Revenue Projections

People Also Watch

Frequently Asked Questions

What is Electromed Inc (ELMD) stock price today?

The current price of ELMD is 29.88 USD — it has increased 0.95 % in the last trading day.

What is Electromed Inc (ELMD)'s business?

Electromed, Inc. develops, manufactures, markets and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function. It applies High Frequency Chest Wall Oscillation (HFCWO) technologies in pulmonary care for patients of all ages. The SmartVest Clearway System consists of an inflatable therapy garment, a programmable air pulse generator and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall. The SmartVest Clearway is designed for comfort and convenience, so patients can readily fit therapy into their daily routines. The SmartVest System is primarily prescribed for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis. It also markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to health care providers in the acute care setting.

What is the price predicton of ELMD Stock?

What is Electromed Inc (ELMD)'s revenue for the last quarter?

Electromed Inc revenue for the last quarter amounts to 16.89M USD, increased 15.13 % YoY.

What is Electromed Inc (ELMD)'s earnings per share (EPS) for the last quarter?

Electromed Inc. EPS for the last quarter amounts to 0.25 USD, increased 56.25 % YoY.

What changes have occurred in the market's expectations for Electromed Inc (ELMD)'s fundamentals?

How many employees does Electromed Inc (ELMD). have?

Electromed Inc (ELMD) has 177 emplpoyees as of December 17 2025.

What is Electromed Inc (ELMD) market cap?

Today ELMD has the market capitalization of 249.22M USD.